Michael Serzan, MD, discusses what a community oncologist should know about the phase 2 ARCITECT trial for patients with clear cell renal cell carcinoma.
Michael Serzan, MD
Advertisement
Michael Serzan, MD, is a medical oncologist in the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute.
Articles by Michael Serzan, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
